Want to see IN:BROOKS full AI Analyst Report?
Top Page
Brooks Laboratories Limited
(BROOKS)
Select Model
Select Model
Rating:60Neutral
Price Target:
₹69.00
▲(8.87% Upside)
Action:Reiterated
Date:09/06/26
The score is primarily supported by the FY2026 profitability turnaround and a low-leverage balance sheet. It is tempered by the steep revenue decline and still-uneven cash flow conversion, while technicals and valuation are both moderate rather than strongly supportive.
Positive Factors
Profitability Turnaround
The return to strong profitability improves internal funding capacity and indicates that the business can generate earnings after several loss-making years, although consistency must still be demonstrated.
Negative Factors
Revenue Contraction
A sharp top-line decline weakens operating scale and raises questions about product demand, customer retention, or competitive position, making the recent earnings recovery harder to assess as durable.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability Turnaround
The return to strong profitability improves internal funding capacity and indicates that the business can generate earnings after several loss-making years, although consistency must still be demonstrated.
Read all positive factors
Brooks Laboratories Limited (BROOKS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹2.02B
Dividend YieldN/A
Average Volume (3M)2.66K
Price to Earnings (P/E)14.1
Beta (1Y)1.66
Revenue Growth-7.71%
EPS Growth927.75%
CountryIN
Employees347
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)4.49
Shares Outstanding29,457,249
10 Day Avg. Volume2,659
30 Day Avg. Volume2,657
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.89
Price to Sales (P/S)1.27
P/FCF Ratio21.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Brooks Laboratories Limited Business Overview & Revenue Model
Company Description
Brooks Laboratories Limited is a pharmaceutical enterprise engaged in the contractual manufacturing and distribution of medicinal products. The company serves both the Indian domestic market and international clients. Its comprehensive product por...
Brooks Laboratories Limited Financial Statement Overview
Summary
Income Statement
58
Neutral
Balance Sheet
78
Positive
Cash Flow
45
Neutral
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 831.87M | 857.38M | 825.57M | 794.86M | 624.80M | 911.85M |
| Gross Profit | 223.77M | 179.65M | 139.22M | 225.13M | 126.02M | -79.11M |
| EBITDA | 133.97M | 270.09M | 58.22M | 41.73M | -291.68M | -134.50M |
| Net Income | 132.12M | 245.84M | -99.67M | -195.92M | -209.00M | -193.13M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 1.48B | 1.24B | 904.45M | 1.10B | 1.96B |
| Cash, Cash Equivalents and Short-Term Investments | 66.73M | 75.49M | 12.48M | 1.25M | 232.00K | 26.05M |
| Total Debt | 0.00 | 85.17M | 75.83M | 56.42M | 65.12M | 252.59M |
| Total Liabilities | -1.23B | 255.17M | 255.90M | 248.60M | 356.44M | 615.91M |
| Stockholders Equity | 1.23B | 1.23B | 981.04M | 655.85M | 739.53M | 874.90M |
Cash Flow | ||||||
| Free Cash Flow | -3.84M | 50.87M | -971.00K | -101.20M | -149.58M | -650.53M |
| Operating Cash Flow | 3.19M | 85.92M | 17.62M | -96.81M | -144.91M | -374.41M |
| Investing Cash Flow | -1.03M | -29.82M | -460.41M | 1.82M | 4.95M | -249.09M |
| Financing Cash Flow | -2.30M | 9.34M | 441.96M | 96.01M | 114.14M | 640.71M |
Brooks Laboratories Limited Technical Analysis
Negative
63.38
Price Trends
65.67
Negative
63.61
Positive
69.36
Negative
Market Momentum
0.68
Negative
48.91
Neutral
55.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BROOKS, the sentiment is Negative. The current price of 63.38 is below the 20-day moving average (MA) of 63.86, below the 50-day MA of 65.67, and below the 200-day MA of 69.36, indicating a neutral trend. The MACD of 0.68 indicates Negative momentum. The RSI at 48.91 is Neutral, neither overbought nor oversold. The STOCH value of 55.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BROOKS.
Brooks Laboratories Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
81 Outperform | ₹1.83B | 12.01 | ― | 0.70% | 4.29% | 2.37% | |
60 Neutral | ₹2.02B | 14.10 | ― | ― | -7.71% | 927.75% | |
59 Neutral | ₹1.48B | 21.01 | ― | 1.05% | 13.51% | -14.80% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹1.30B | 37.60 | ― | ― | 0.46% | -86.65% | |
53 Neutral | ₹2.77B | 66.69 | ― | 0.23% | -7.69% | -0.16% | |
48 Neutral | ₹2.36B | -1.07 | ― | 20.72% | -99.53% | -41.93% |
* General Sector Average
IN:BROOKS
Brooks Laboratories Limited
63.96
-82.79
-56.42%
IN:AAREYDRUGS
Aarey Drugs & Pharmaceuticals Ltd.
97.12
26.25
37.04%
IN:ALPA
Alpa Laboratories Limited
61.87
-33.18
-34.91%
IN:BALPHARMA
Bal Pharma Limited
95.02
7.71
8.83%
IN:NECLIFE
Nectar Lifesciences Ltd.
12.29
-1.78
-12.65%
IN:PAR
Par Drugs and Chemicals Limited
141.44
33.34
30.84%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.